Ingersoll Rand Inc. has announced the acquisition of Dave Barry Plastics, further enhancing its life sciences portfolio. This strategic move aligns with Ingersoll Rand's commitment to expanding its offerings with high-performance solutions. Dave Barry Plastics, based in Ireland, specializes in designing and manufacturing custom plastic products for the biopharmaceutical, pharmaceutical, and medical device industries. The acquisition is expected to bolster Ingersoll Rand's capabilities within the life sciences sector, particularly in providing solutions for clean rooms. The transaction was made at an attractive purchase multiple of approximately 9x 2024 Adjusted EBITDA, emphasizing Ingersoll Rand's strategy of growth through direct investments and strong relationships with family-owned businesses.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。